The subjective effects of MDMA and mCPP in moderate MDMA users
The present study is part of a research program designed to better understand the neurochemical mechanisms underlying the abuse liability of 3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will be compared to prototypical dopamine ( d-amphetamine) and serotonin ( meta-chlo...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol dependence 2001-12, Vol.65 (1), p.97-101 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101 |
|---|---|
| container_issue | 1 |
| container_start_page | 97 |
| container_title | Drug and alcohol dependence |
| container_volume | 65 |
| creator | Tancer, Manuel E. Johanson, Chris-Ellyn |
| description | The present study is part of a research program designed to better understand the neurochemical mechanisms underlying the abuse liability of 3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will be compared to prototypical dopamine (
d-amphetamine) and serotonin (
meta-chlorophenylpiperazine,
mCPP) releasing agents on a variety of measures related to dependence. In order to determine an acceptable dose range (safe but active) of MDMA and
mCPP for these studies, moderate MDMA users were administered escalating doses of MDMA (75, 110 and 145 mg/70 kg) and
mCPP (17.5, 35 and 52.5 mg/70 kg). Each participant received a single dose under controlled laboratory conditions, i.e. this was a six-group design with a separate group for each dose. There were five participants tested in each group. MDMA increased blood pressure and heart rate whereas
mCPP had no effect on these physiological measures. MDMA produced increases in subjective effects indicative of both stimulant (increases in POMS Elation, ARCI Amphetamine, VAS High and Stimulated scale scores) and hallucinogenic effects (increases on five of the six scales of the Hallucinogenic Rating Scale).
mCPP produced similar stimulant effects (e.g. increases on POMS Elation, VAS High and Stimulated), as well as hallucinogenic effects (four of the six scales of the Hallucinogenic Rating Scale), which has not been observed in previous studies. |
| doi_str_mv | 10.1016/S0376-8716(01)00146-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_57851872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871601001466</els_id><sourcerecordid>57851872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-2c83b1f13ee03890cac63d4fa8cc2302e86cb1a95db182c98c3b646d22228b063</originalsourceid><addsrcrecordid>eNqFkF1LwzAUhoMobk5_gtIbRS-qSdOm6Y0y5idsOHBehzQ5xYx-zKQd-O9t1-IuPTcJnCfnPXkQOif4lmDC7j4wjZnPY8KuMbnBmITMZwdoTHic-BiH7BCN_5AROnFujdtiCT5GI0JiEkZJOEb3qy_wXJOuQdVmCx5kWXtzXpV5i8fF1JOl9orZcumZ0isqDVbW0HcaB9adoqNM5g7OhnOCPp-fVrNXf_7-8jabzn0VBkHtB4rTlGSEAmDKE6ykYlSHmeRKBRQHwJlKiUwinRIeqIQrmrKQ6aAtnmJGJ-iqn7ux1XcDrhaFcQryXJZQNU5EMY_anwctGPWgspVzFjKxsaaQ9kcQLDpxYidOdFYEJmInTnQBF0NAkxag968GUy1wOQDSKZlnVpbKuD1HaRzHSTfooeeg1bE1YIVTBkoF2tjWrNCV-WeVX6dnh2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>57851872</pqid></control><display><type>article</type><title>The subjective effects of MDMA and mCPP in moderate MDMA users</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Tancer, Manuel E. ; Johanson, Chris-Ellyn</creator><creatorcontrib>Tancer, Manuel E. ; Johanson, Chris-Ellyn</creatorcontrib><description>The present study is part of a research program designed to better understand the neurochemical mechanisms underlying the abuse liability of 3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will be compared to prototypical dopamine (
d-amphetamine) and serotonin (
meta-chlorophenylpiperazine,
mCPP) releasing agents on a variety of measures related to dependence. In order to determine an acceptable dose range (safe but active) of MDMA and
mCPP for these studies, moderate MDMA users were administered escalating doses of MDMA (75, 110 and 145 mg/70 kg) and
mCPP (17.5, 35 and 52.5 mg/70 kg). Each participant received a single dose under controlled laboratory conditions, i.e. this was a six-group design with a separate group for each dose. There were five participants tested in each group. MDMA increased blood pressure and heart rate whereas
mCPP had no effect on these physiological measures. MDMA produced increases in subjective effects indicative of both stimulant (increases in POMS Elation, ARCI Amphetamine, VAS High and Stimulated scale scores) and hallucinogenic effects (increases on five of the six scales of the Hallucinogenic Rating Scale).
mCPP produced similar stimulant effects (e.g. increases on POMS Elation, VAS High and Stimulated), as well as hallucinogenic effects (four of the six scales of the Hallucinogenic Rating Scale), which has not been observed in previous studies.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/S0376-8716(01)00146-6</identifier><identifier>PMID: 11714594</identifier><identifier>CODEN: DADEDV</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>3,4-Methylenedioxymethamphetamine ; Addictive behaviors ; Adolescent ; Adult ; Adult and adolescent clinical studies ; Affect - drug effects ; Affect - physiology ; Analysis of Variance ; Biological and medical sciences ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug abuse ; Drug addiction ; Drug addictions ; Female ; Hallucinogenic rating scale ; Hallucinogens - administration & dosage ; Heart Rate - drug effects ; Heart Rate - physiology ; Humans ; Male ; Medical sciences ; meta-Chlorophenylpiperazine ; N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage ; Piperazines - administration & dosage ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Serotonin Receptor Agonists - administration & dosage ; Subjective experiences ; Substance-Related Disorders - psychology ; Toxicology</subject><ispartof>Drug and alcohol dependence, 2001-12, Vol.65 (1), p.97-101</ispartof><rights>2001 Elsevier Science Ireland Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-2c83b1f13ee03890cac63d4fa8cc2302e86cb1a95db182c98c3b646d22228b063</citedby><cites>FETCH-LOGICAL-c422t-2c83b1f13ee03890cac63d4fa8cc2302e86cb1a95db182c98c3b646d22228b063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0376-8716(01)00146-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,30999,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13377796$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11714594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tancer, Manuel E.</creatorcontrib><creatorcontrib>Johanson, Chris-Ellyn</creatorcontrib><title>The subjective effects of MDMA and mCPP in moderate MDMA users</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>The present study is part of a research program designed to better understand the neurochemical mechanisms underlying the abuse liability of 3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will be compared to prototypical dopamine (
d-amphetamine) and serotonin (
meta-chlorophenylpiperazine,
mCPP) releasing agents on a variety of measures related to dependence. In order to determine an acceptable dose range (safe but active) of MDMA and
mCPP for these studies, moderate MDMA users were administered escalating doses of MDMA (75, 110 and 145 mg/70 kg) and
mCPP (17.5, 35 and 52.5 mg/70 kg). Each participant received a single dose under controlled laboratory conditions, i.e. this was a six-group design with a separate group for each dose. There were five participants tested in each group. MDMA increased blood pressure and heart rate whereas
mCPP had no effect on these physiological measures. MDMA produced increases in subjective effects indicative of both stimulant (increases in POMS Elation, ARCI Amphetamine, VAS High and Stimulated scale scores) and hallucinogenic effects (increases on five of the six scales of the Hallucinogenic Rating Scale).
mCPP produced similar stimulant effects (e.g. increases on POMS Elation, VAS High and Stimulated), as well as hallucinogenic effects (four of the six scales of the Hallucinogenic Rating Scale), which has not been observed in previous studies.</description><subject>3,4-Methylenedioxymethamphetamine</subject><subject>Addictive behaviors</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Affect - drug effects</subject><subject>Affect - physiology</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure - physiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug abuse</subject><subject>Drug addiction</subject><subject>Drug addictions</subject><subject>Female</subject><subject>Hallucinogenic rating scale</subject><subject>Hallucinogens - administration & dosage</subject><subject>Heart Rate - drug effects</subject><subject>Heart Rate - physiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>meta-Chlorophenylpiperazine</subject><subject>N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage</subject><subject>Piperazines - administration & dosage</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Serotonin Receptor Agonists - administration & dosage</subject><subject>Subjective experiences</subject><subject>Substance-Related Disorders - psychology</subject><subject>Toxicology</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkF1LwzAUhoMobk5_gtIbRS-qSdOm6Y0y5idsOHBehzQ5xYx-zKQd-O9t1-IuPTcJnCfnPXkQOif4lmDC7j4wjZnPY8KuMbnBmITMZwdoTHic-BiH7BCN_5AROnFujdtiCT5GI0JiEkZJOEb3qy_wXJOuQdVmCx5kWXtzXpV5i8fF1JOl9orZcumZ0isqDVbW0HcaB9adoqNM5g7OhnOCPp-fVrNXf_7-8jabzn0VBkHtB4rTlGSEAmDKE6ykYlSHmeRKBRQHwJlKiUwinRIeqIQrmrKQ6aAtnmJGJ-iqn7ux1XcDrhaFcQryXJZQNU5EMY_anwctGPWgspVzFjKxsaaQ9kcQLDpxYidOdFYEJmInTnQBF0NAkxag968GUy1wOQDSKZlnVpbKuD1HaRzHSTfooeeg1bE1YIVTBkoF2tjWrNCV-WeVX6dnh2Y</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>Tancer, Manuel E.</creator><creator>Johanson, Chris-Ellyn</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>20011201</creationdate><title>The subjective effects of MDMA and mCPP in moderate MDMA users</title><author>Tancer, Manuel E. ; Johanson, Chris-Ellyn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-2c83b1f13ee03890cac63d4fa8cc2302e86cb1a95db182c98c3b646d22228b063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>3,4-Methylenedioxymethamphetamine</topic><topic>Addictive behaviors</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Affect - drug effects</topic><topic>Affect - physiology</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure - physiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug abuse</topic><topic>Drug addiction</topic><topic>Drug addictions</topic><topic>Female</topic><topic>Hallucinogenic rating scale</topic><topic>Hallucinogens - administration & dosage</topic><topic>Heart Rate - drug effects</topic><topic>Heart Rate - physiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>meta-Chlorophenylpiperazine</topic><topic>N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage</topic><topic>Piperazines - administration & dosage</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Serotonin Receptor Agonists - administration & dosage</topic><topic>Subjective experiences</topic><topic>Substance-Related Disorders - psychology</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tancer, Manuel E.</creatorcontrib><creatorcontrib>Johanson, Chris-Ellyn</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tancer, Manuel E.</au><au>Johanson, Chris-Ellyn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The subjective effects of MDMA and mCPP in moderate MDMA users</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>65</volume><issue>1</issue><spage>97</spage><epage>101</epage><pages>97-101</pages><issn>0376-8716</issn><eissn>1879-0046</eissn><coden>DADEDV</coden><abstract>The present study is part of a research program designed to better understand the neurochemical mechanisms underlying the abuse liability of 3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will be compared to prototypical dopamine (
d-amphetamine) and serotonin (
meta-chlorophenylpiperazine,
mCPP) releasing agents on a variety of measures related to dependence. In order to determine an acceptable dose range (safe but active) of MDMA and
mCPP for these studies, moderate MDMA users were administered escalating doses of MDMA (75, 110 and 145 mg/70 kg) and
mCPP (17.5, 35 and 52.5 mg/70 kg). Each participant received a single dose under controlled laboratory conditions, i.e. this was a six-group design with a separate group for each dose. There were five participants tested in each group. MDMA increased blood pressure and heart rate whereas
mCPP had no effect on these physiological measures. MDMA produced increases in subjective effects indicative of both stimulant (increases in POMS Elation, ARCI Amphetamine, VAS High and Stimulated scale scores) and hallucinogenic effects (increases on five of the six scales of the Hallucinogenic Rating Scale).
mCPP produced similar stimulant effects (e.g. increases on POMS Elation, VAS High and Stimulated), as well as hallucinogenic effects (four of the six scales of the Hallucinogenic Rating Scale), which has not been observed in previous studies.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>11714594</pmid><doi>10.1016/S0376-8716(01)00146-6</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-8716 |
| ispartof | Drug and alcohol dependence, 2001-12, Vol.65 (1), p.97-101 |
| issn | 0376-8716 1879-0046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_57851872 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Journals (5 years ago - present) |
| subjects | 3,4-Methylenedioxymethamphetamine Addictive behaviors Adolescent Adult Adult and adolescent clinical studies Affect - drug effects Affect - physiology Analysis of Variance Biological and medical sciences Blood Pressure - drug effects Blood Pressure - physiology Dose-Response Relationship, Drug Double-Blind Method Drug abuse Drug addiction Drug addictions Female Hallucinogenic rating scale Hallucinogens - administration & dosage Heart Rate - drug effects Heart Rate - physiology Humans Male Medical sciences meta-Chlorophenylpiperazine N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage Piperazines - administration & dosage Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Serotonin Receptor Agonists - administration & dosage Subjective experiences Substance-Related Disorders - psychology Toxicology |
| title | The subjective effects of MDMA and mCPP in moderate MDMA users |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20subjective%20effects%20of%20MDMA%20and%20mCPP%20in%20moderate%20MDMA%20users&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Tancer,%20Manuel%20E.&rft.date=2001-12-01&rft.volume=65&rft.issue=1&rft.spage=97&rft.epage=101&rft.pages=97-101&rft.issn=0376-8716&rft.eissn=1879-0046&rft.coden=DADEDV&rft_id=info:doi/10.1016/S0376-8716(01)00146-6&rft_dat=%3Cproquest_cross%3E57851872%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=57851872&rft_id=info:pmid/11714594&rft_els_id=S0376871601001466&rfr_iscdi=true |